Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Non-HFE hemochromatosis.

Antonello Pietrangelo1

  • 1Center for Hemochromatosis and Hereditary Liver Diseases, Department of Internal Medicine, University of Modena and Reggio Emilia, Policlinico, Modena, Italy. pietrangelo.antonello@unimore.it

Seminars in Liver Disease
|November 30, 2005
PubMed
Summary

Non-HFE hemochromatosis (non-HFE HC) encompasses genetic disorders without HFE mutations, involving TfR2, HJV, and HAMP genes. These conditions impact iron homeostasis, potentially leading to earlier and more severe symptoms than classic hereditary hemochromatosis.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Characterization of ferroportin disease and SLC40A1-related hemochromatosis - Results from the EASL non-HFE registry.

Journal of hepatology·2026
Same author

Genome-wide association for sarcoidosis identifies novel risk loci and genetic heritability in African and European ancestries: a meta-analysis from the Finngen, Million Veteran Program, UK Biobank, and Biobank Japan datasets.

Orphanet journal of rare diseases·2025
Same author

Alterations in iron status predict cardiac response to blood transfusion in β-thalassemia major.

Scientific reports·2025
Same author

Lipidic nanomedicines enhance Hinokitiol activity on human primary macrophages from Ferroportin disease patients.

International journal of pharmaceutics·2025
Same author

Porphyrias: Pathophysiology and clinical management recommendations for hepatologists.

Hepatology communications·2025
Same author

Diagnosis and Management of Non-HFE Hemochromatosis, Ferroportin Disease, and Rare Hereditary Iron-Loading Disorders.

Advances in experimental medicine and biology·2025

Area of Science:

  • Genetics and molecular biology of iron metabolism disorders.
  • Clinical and pathophysiological characterization of hereditary hemochromatosis.

Background:

  • Hereditary hemochromatosis (HC) is often associated with HFE gene mutations.
  • Non-HFE hemochromatosis (non-HFE HC) comprises distinct genetic forms without HFE mutations.
  • Key genes involved in non-HFE HC include transferrin receptor 2 (TfR2), hemojuvelin (HJV), and hepcidin (HAMP).

Purpose of the Study:

  • To differentiate non-HFE HC from other hereditary iron overload conditions.
  • To elucidate the role of TfR2, HJV, and HAMP in iron homeostasis and disease pathogenesis.
  • To compare clinical features and onset of non-HFE HC with HFE-associated HC.

Main Methods:

  • Review and synthesis of existing literature on non-HFE HC genetics and clinical presentations.

Related Experiment Videos

  • Comparative analysis of pathogenic mechanisms and phenotypic expressivity across different HC forms.
  • Examination of the central role of non-HFE HC gene products in human iron metabolism.

    • Main Results:

    • Non-HFE HC variants share clinical similarities with HFE HC but can present earlier and more severely.
    • Ferroportin disease is a distinct hereditary iron overload with autosomal dominant inheritance and specific iron distribution.
    • Genes implicated in non-HFE HC (TfR2, HJV, HAMP) play critical roles in iron trafficking, distinct from HFE.

    Conclusions:

    • Non-HFE HC represents a spectrum of disorders crucial for understanding iron metabolism.
    • Understanding the function of TfR2, HJV, and HAMP is vital for advancing knowledge of iron homeostasis.
    • These genes, while causing rarer forms of HC, are more central to iron regulation than HFE.